Lanopepden Mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565646

CAS#: 1441390-17-5

Description: Lanopepden Mesylate is a novel peptide deformylase inhibitor against streptococcus pneumoniae, haemophilus influenzae, and staphylococcus aureus

Price and Availability




is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 565646
Name: Lanopepden Mesylate
CAS#: 1441390-17-5
Chemical Formula: C23H38FN7O7S
Exact Mass: 575.2537
Molecular Weight: 575.6574
Elemental Analysis: C, 47.99; H, 6.65; F, 3.30; N, 17.03; O, 19.45; S, 5.57

Synonym: GSK-1322322A; GSK 1322322A; GSK1322322A; GSK-322A; GSK 322A; GSK322A

IUPAC/Chemical Name: N-((R)-2-(Cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazineyl)-3-oxopropyl)-N-hydroxyformamide Mesylate


InChi Code: InChI=1S/C22H34FN7O4.CH4O3S/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16;1-5(2,3)4/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26);1H3,(H,2,3,4)/t17-,18+;/m1./s1

SMILES Code: O=CN(C[C@@H](CC1CCCC1)C(NNC2=NC(C)=NC(N3C[C@@]4([H])COCCN4CC3)=C2F)=O)O.OS(=O)(C)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Maral S, Bakanay SM, Kucuksahin O, Dilek I. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib. J Oncol Pharm Pract. 2019 Jul 30:1078155219863469. doi: 10.1177/1078155219863469. [Epub ahead of print] PubMed PMID: 31359838.

2: Li G, Chan YL, Sukjamnong S, Anwer AG, Vindin H, Padula M, Zakarya R, George J, Oliver BG, Saad S, Chen H. A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. Nutrients. 2019 Jul 21;11(7). pii: E1669. doi: 10.3390/nu11071669. PubMed PMID: 31330878.

3: Lind J, Czernilofsky F, Vallet S, Podar K. Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opin Emerg Drugs. 2019 Jul 29:1-20. doi: 10.1080/14728214.2019.1647165. [Epub ahead of print] PubMed PMID: 31327278.

4: Hung KD, Van QL, Hoang GN, Bich PNT. Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam. Cancer Control. 2019 Jan-Dec;26(1):1073274819863776. doi: 10.1177/1073274819863776. PubMed PMID: 31319677.

5: Lunge S, Bhise R. Imatinib Mesylate Induced Erythroderma. J Assoc Physicians India. 2018 Dec;66(12):79-80. PubMed PMID: 31313559.

6: Wejih DM, Leila GE, Ali CM, Ramzi N, Ibtissem B, Chadli D. Rectal stromal tumor with an exceptional liver and bone metastatic locations. Pan Afr Med J. 2019 Mar 20;32:133. doi: 10.11604/pamj.2019.32.133.17985. eCollection 2019. PubMed PMID: 31303906; PubMed Central PMCID: PMC6607269.

7: Liu X, Deng L, Guo R, Liang Q, Liu S, Hu P. [Evaluation of total liver perfusion imaging of CT for efficacy of transcatheter arterial chemoembolization combined with apatinib on rabbit VX2 liver tumors]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 May 28;44(5):477-484. doi: 10.11817/j.issn.1672-7347.2019.05.002. Chinese. PubMed PMID: 31303609.

8: Han JM, Yee J, Cho YS, Gwak HS. Factors Influencing Imatinib-Induced Hepatotoxicity. Cancer Res Treat. 2019 Jun 26. doi: 10.4143/crt.2019.131. [Epub ahead of print] PubMed PMID: 31291714.

9: Bagum H, Christensen KE, Genov M, Pretsch A, Pretsch D, Moloney MG. Synthetic Access to 3-Substituted Pyroglutamic Acids from Tetramate Derivatives of Serine, Threonine, allo-Threonine, and Cysteine. J Org Chem. 2019 Jul 29. doi: 10.1021/acs.joc.9b01432. [Epub ahead of print] PubMed PMID: 31287955.

10: Dhangar S, Shanbhag V, Shanmukhaiah C, Vundinti BR. Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients. Mol Biol Rep. 2019 Jul 8. doi: 10.1007/s11033-019-04950-0. [Epub ahead of print] PubMed PMID: 31286393.

11: Ahmadi N, Samaee SM, Yokel RA, Tehrani A. Imatinib mesylate effects on zebrafish reproductive success: Gonadal development, gamete quality, fertility, embryo-larvae viability and development, and related genes. Toxicol Appl Pharmacol. 2019 Jul 3;379:114645. doi: 10.1016/j.taap.2019.114645. [Epub ahead of print] PubMed PMID: 31278918.

12: Karolewicz B, Górniak A, Marciniak DM, Mucha I. Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate. Pharmaceutics. 2019 Jul 1;11(7). pii: E304. doi: 10.3390/pharmaceutics11070304. PubMed PMID: 31266220.

13: Rathore AP, Mantri CK, Aman SA, Syenina A, Ooi J, Jagaraj CJ, Goh CC, Tissera H, Wilder-Smith A, Ng LG, Gubler DJ, St John AL. Dengue virus-elicited tryptase induces endothelial permeability and shock. J Clin Invest. 2019 Jul 2;130. pii: 128426. doi: 10.1172/JCI128426. PubMed PMID: 31265436.

14: Kim JY, Kim HS, Yoon S. Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. Anticancer Res. 2019 Jul;39(7):3785-3793. doi: 10.21873/anticanres.13527. PubMed PMID: 31262905.

15: Komi DEA, Redegeld FA. Role of Mast Cells in Shaping the Tumor Microenvironment. Clin Rev Allergy Immunol. 2019 Jun 29. doi: 10.1007/s12016-019-08753-w. [Epub ahead of print] Review. PubMed PMID: 31256327.

16: Vetrugno L, Tomasino S, Battezzi A, Parisella L, Bernardinetti M, Bove T. Cardiac tamponade and graft versus host disease: one more reason to remember. Tumori. 2018 Dec;104(6):NP14-NP16. doi: 10.1177/0300891618794890. PubMed PMID: 31248337.

17: Cai Z, Chen X, Zhang B, Cao D. Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor. Front Oncol. 2019 Jun 11;9:470. doi: 10.3389/fonc.2019.00470. eCollection 2019. PubMed PMID: 31245289; PubMed Central PMCID: PMC6579896.

18: Sakai K, Ikeda T, Ishida C, Komai K, Yamada M. Delusions and visual hallucinations in a patient with Parkinson's disease with dementia showing pronounced Lewy body pathology in the nucleus basalis of Meynert. Neuropathology. 2019 Jun 26. doi: 10.1111/neup.12581. [Epub ahead of print] PubMed PMID: 31243794.

19: Ouahbi H, Amadour L, Elmernissi F, Tahiri L, Harmouch T, Benbrahim Z, Elmrabet F, Arifi S, Oufkigh AA, Mellas N. [Outcome of locally advanced Darier and Ferrand dermatofibrosarcoma: about a case and literature review]. Pan Afr Med J. 2019 Feb 28;32:97. doi: 10.11604/pamj.2019.32.97.10293. eCollection 2019. Review. French. PubMed PMID: 31223387; PubMed Central PMCID: PMC6560964.

20: Sener Y, Okay M, Aydin S, Buyukasik Y, Akbiyik F, Dikmen ZG. TKI-Related Platelet Dysfunction Does Not Correlate With Bleeding in Patients With Chronic Phase-Chronic Myeloid Leukemia With Complete Hematological Response. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619858409. doi: 10.1177/1076029619858409. PubMed PMID: 31218883.